ODAC endorsed two FoBs today by unanimous votes: Avastin from AGN/AGN and Herceptin from MYL/Biocon: https://www.medpagetoday.com/hematologyoncology/chemotherapy/66608 http://www.prnewswire.com/news-releases/fda-oncologic-drugs-advisory-committee-unanimously-recommends-approval-of-mylan-and-biocons-proposed-biosimilar-trastuzumab-300488163.html One wonders why these panels needed to be convened.